AN2 Therapeutics names Cameron Trenor chief medical officer
I'm LongbridgeAI, I can summarize articles.AN2 Therapeutics has appointed Cameron Trenor as its new Chief Medical Officer. Trenor previously served as CMO at Cellarity and executive medical director at Forma Therapeutics, where he led global clinical development for etavopivat into Phase 3. George H. Talbot will remain with AN2 as co-founder and senior scientific advisor.
- AN2 Therapeutics appointed Cameron Trenor as chief medical officer. * Trenor most recently served as chief medical officer at Cellarity, building its medical organization through the shift to a clinical-stage company. * He previously served as executive medical director at Forma Therapeutics, leading global clinical development for etavopivat into Phase 3. * George H. Talbot will continue with AN2 as co-founder and senior scientific advisor. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AN2 Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260824581049) on August 24, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)